Delivery Order SPE2DB22D1202-SPE2DB25FVGH4
- Not listed
- The Defense Logistics Agency awarded a $6,007.38 delivery order to AmerisourceBergen Drug Corp on July 1, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors. This firm fixed-price contract, with an ultimate completion date of July 2, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The award was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections with a ceiling value of $1,143.87 and an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999, which runs through...
- The Defense Logistics Agency awarded a $10,814.13 firm fixed price delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injectors with a completion date of June 2, 2025. This non-set-aside competitive award represents a continuation of services under AmerisourceBergen's broader pharmaceutical supply arrangement with the federal government. The delivery order is being fulfilled from the company's place of business in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pens in 0.5 mL quantities, with a ceiling value of $8,408.08. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 2, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply...
- The Defense Logistics Agency awarded a $2,383.56 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pen injections. This non-competitive delivery order, with an ultimate completion date of July 15, 2025, represents a small-value pharmaceutical transaction supporting federal medical procurement needs. The award was fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a $25,617.61 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injections. This is a firm fixed price, competitively awarded contract with an ultimate completion date of July 23, 2025, and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the company's headquarters in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $9,927.33 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen injectors on April 24, 2025, with completion scheduled for April 25, 2025. This firm fixed-price, competitively awarded delivery order represents a continuation of AmerisourceBergen's substantial role as a critical pharmaceutical supplier to the federal government. The order will be fulfilled from the contractor's location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $1,525.20 to AmerisourceBergen Drug Corp for the supply of Zepbound 12.5 mg/0.5 ml pen injections on July 24, 2025. This firm fixed-price, competitively awarded contract is classified as a delivery order with no set-aside designation and carries an ultimate completion date of July 25, 2025. The pharmaceutical product will be performed from AmerisourceBergen's location in Conshohocken, Pennsylvania, the company's corporate...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injectors in 0.5 mL quantities, with a contract ceiling value of $8,359.40 and an ultimate completion date of June 20, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal military and veteran healthcare...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for $3,431.61 on August 21, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectors. This firm fixed-price, non-set-aside delivery order is scheduled for completion by August 22, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a small-value transaction under AmerisourceBergen's larger relationship...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVGH4Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections with a ceiling value of $7,625.80. This competitively awarded, firm fixed-price contract is classified as a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at $999,999,999.00 through December 2026. The delivery order is scheduled for completion by August 5, 2025, with the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order exemplifies AmerisourceBergen's critical role as a pharmaceutical prime vendor supporting federal military and healthcare systems. The company's comprehensive IDC vehicle enables it to supply an extensive portfolio of pharmaceutical products and medical supplies to support Defense Health Agency and other government healthcare programs globally. AmerisourceBergen's track record of competitively awarded delivery orders across multiple therapeutic domains, including diabetes medications and specialty pharmaceuticals, demonstrates its capability to fulfill federal medical procurement requirements efficiently and reliably.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.6k | 8/4/25 |